News | October 08, 2024
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
CSPC will receive an upfront payment of $100 million from AstraZeneca
The company will also share results in two additional posters for deuruxolitinib
ALS patients experience neuroinflammation and rapid neurodegeneration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Subscribe To Our Newsletter & Stay Updated
